Abstract
BRAF inhibitor vemurafenib achieved improved overall survival over chemotherapy and have been approved by the FDA and EMA for the treatment of BRAF-mutated metastatic melanoma. The aim of our retrospective analysis was to determine the efficacy and safety of vemurafenib therapy for BRAF mutated metastatic melanoma and subsequently to prove the clinical benefit for the studied 43 patients, based on real-life data. From November 2012 to October 2015 we have selected 43 BRAF mutated, metastatic melanoma patients, treated with vemurafenib. The median follow-up time was 15.9 months. We evaluated progression free survival (PFS), overall survival (OS) and toxicities. According to the AJCC staging system 70% of the patients had stage M1c metastasis, including 6 with stable brain metastasis. Objective responses were noted in 51.1%, the disease control rate was achieved in 79% of the patients. Complete responses were attained by 5 patients (11.6%). Median PFS was 6.48 (95% CI:4.8–15.0) months, median OS was 11.47 (95% CI:8.08-NA) months. We found significant association between LDH level and OS in univariate (p = 0.000613) and multivariate analysis (p = 0.0168). The most common adverse events (AEs) included follicular hyperkeratosis, rash, arthralgia and photosensitivity. Grade 3 AEs, such as cutaneous squamous-cell carcinoma, QTcB interval prolongation, rash, arthralgia were reported in 7 patients (17%). We had no Grade 4 side effects. Similar to the previously published data our analysis confirms the improved survival with vemurafenib treatment (11.47 months) in patients with BRAF V600 mutation. Vemurafenib therapy was well tolerated, the AE profile was almost consistent with the previously reported data of randomised clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254
Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998–1012
Hodi FS, O'Day SJ, McDermott DF, Weber RW et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723 Erratum in: N Engl J Med. 363(13):1290
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323–332
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Hauschild A et al (2012) Dabrafenib in BRAF-mutated metastatuc melanoma:a multicentre, open-label, phase 3 randomized controlled trial. Lancet 9839:358–365
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA et al (2010) Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 363:809–819
Sosman JA, Kevin MD et al (2012) Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib. N Engl J Med 366:707–714
Asić K (2016) Dominant mechanisms of primary resistance differ from dominat mechanisms of secondary resistance to target therapies. Crit Rev Oncol Hematol 97:178–196
Trunzer K, Pavlick AC, Sosman JA, Ribas A et al (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31(14):1767–1774
Rinderknecht JD, Goldinger SM et al (2013) RASopathic Skin Eruptions during Vemurafenib Therapy. PlosOne 8(10) https://doi.org/10.1371/annotation/d884b668-04f7-4ae6-96a3-a199df5b43be. 2013 March 14
Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A et al (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148(3):357–361
Manzano Jose L, Layos L et al (2016) Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med 4(12):237
Larkin J, Ascierto PA, Dreno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876
Ascierto PA, McArthur et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260
Long G et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val 600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised, controlled trial. Lancet 386:444–451
Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma combined dabrafenib and trametinib. N Engl J Med 372:30–39
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Czirbesz, K., Gorka, E., Balatoni, T. et al. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Pathol. Oncol. Res. 25, 45–50 (2019). https://doi.org/10.1007/s12253-017-0324-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-017-0324-1